Comparison of change in global brain structures between patients receiving methylphenidate versus placebo after 52 weeks (1-year sample)
| Visit; mean ± SD, mm3 | ||||||
|---|---|---|---|---|---|---|
| Variable | Week 0 | Week 13 | Week 52 | Statistic | p value | |
| Grey matter | ||||||
| MPH | 647.24 ± 67.0 | 644.45 ± 67.1 | 646.89 ± 67.4 | Cohort | F1,63 = 1.02 | 0.32† |
| Placebo | 631.54 ± 60.5 | 628.78 ± 58.9 | 628.20 ± 56.7 | |||
| Visit | F2,128 = 1.44; p = 0.24* | Cohort × visit | F2,128 = 0.54 | 0.58‡ | ||
| White matter | ||||||
| MPH | 523.99 ± 69.8 | 526.07 ± 71.7 | 524.93 ± 69.0 | Cohort | F1,63 = 0.27 | 0.60† |
| Placebo | 514.36 ± 57.1 | 516.32 ± 57.3 | 516.84 ± 59.9 | |||
| Visit | F2,128 = 1.88; p = 0.16* | Cohort × visit | F2,128 = 0.34 | 0.71‡ | ||
| CSF | ||||||
| MPH | 223.06 ± 28.0 | 222.50 ± 26.7 | 222.84 ± 27.9 | Cohort | F1,63 = 0.34 | 0.56† |
| Placebo | 227.68 ± 40.2 | 227.00 ± 40.5 | 227.32 ± 42.6 | |||
| Visit | F2,128 = 0.22; p = 0.80* | Cohort × visit | F2,128 = 0.00 | > 0.99‡ | ||
CSF = cerebrospinal fluid; MPH = methylphenidate.
↵* Effect of visit in mixed-model statistic with covariate group psychotherapy versus clinical management.
↵† Effect of cohort in mixed-model statistic with covariate group psychotherapy versus clinical management.
↵‡ Cohort × visit interaction in mixed-model statistic with covariate group psychotherapy versus clinical management.